Last reviewed · How we verify
Alvelestat oral tablet - dose 1
Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue.
Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue. Used for Alpha-1 antitrypsin deficiency-associated lung disease, Acute respiratory distress syndrome.
At a glance
| Generic name | Alvelestat oral tablet - dose 1 |
|---|---|
| Also known as | MPH966 |
| Sponsor | Mereo BioPharma |
| Drug class | Neutrophil elastase inhibitor |
| Target | Neutrophil elastase |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
By inhibiting neutrophil elastase, alvelestat aims to reduce inflammation and tissue damage in the lungs, which is particularly relevant in conditions such as alpha-1 antitrypsin deficiency-associated lung disease and acute respiratory distress syndrome.
Approved indications
- Alpha-1 antitrypsin deficiency-associated lung disease
- Acute respiratory distress syndrome
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- COVID-19 Study of Safety and Tolerability of Alvelestat (PHASE1, PHASE2)
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (PHASE2)
- Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alvelestat oral tablet - dose 1 CI brief — competitive landscape report
- Alvelestat oral tablet - dose 1 updates RSS · CI watch RSS
- Mereo BioPharma portfolio CI